Aims Recent studies have demonstrated the importance of chromatin remodelling via histone acetylation/deacetylation for the control of cardiac gene expression. Specific histone deacetylases (HDACs) can, in fact, play a positive or negative role in determining cardiac myocyte (CM) size. Here, we report on the effect on hypertrophy development of three inhibitors (HDACi) of class I HDACs.
Introduction
Histone deacetylases (HDACs) remodel chromatin in a genespecific fashion by changing nucleosomal packaging of DNA: deacetylation of histones H3 and H4 by HDACs inhibits transcription, whereas their acetylation by histone acetyltransferases (HATs) results in transcriptional activation. 1 HDACs, thus, can regulate important cellular functions through gene expression control. In particular, regulation of histone acetylation is implicated in proper cell function, differentiation, and cell growth. 2, 3 The pharmacological inhibition of HDACs has, therefore, raised significant interest in the pharmaceutical industry particularly in the search for new anti-proliferative molecules.
Mammalian HDACs can be divided into four classes based on their sequence motifs and catalytic mechanisms. 4, 5 Class I, II, and IV HDACs are evolutionarily related Zn þ -dependent hydrolases. The members of class I (HDAC1, -2, -3, and -8) are expressed ubiquitously and consist mainly of a deacetylase domain. Class II HDACs (HDAC4, -5, -7, and -9) are highly expressed in muscle, brain, and T cells. They have an extended N-terminus, which serves as a target for proteinprotein interactions and for post-translational modifications, such as phosphorylation, important for their function and governing nuclear-cytoplasmic shuttling. 6 HDAC11 is considered to be structurally diverse enough from the other Zn þdependent HDACs to be classified as a separate class (class IV). 7 Class III HDACs are related to the yeast HDAC, silent information regulator 2, and use nicotinamide adenine dinucleotide as a co-substrate. 8 With regard to myocardial hypertrophy, studies have demonstrated that HDACs suppress this process. 9, 10 Moreover, † These authors contributed equally to the work. inhibition of general HDAC activity has also been reported to suppress hypertrophy. 11, 12 It was suggested that different classes of HDACs suppress distinct sets of hypertrophic program-influencing genes. For example, whereas class II HDACs suppress pro-hypertrophic genes, class I HDACs might repress expression of anti-hypertrophic genes. If the antihypertrophic gene products were dominant over the genes suppressed by class II HDACs, one would expect HDAC inhibitors to block hypertrophy. Accordingly, inhibition of class I HDACs would result in a de-repression of such antihypertrophic genes and consequently block hypertrophy. There is evidence for a potential role of class I HDACs in cardiac growth, but the mechanism is still undefined and even less clear than for class II HDACs. 13, 14 In addition, evidence from rodent models indicates that cardiac function is preserved when hypertrophy is inhibited in the face of stress signalling. This points to the potential importance of therapeutic strategies that modulate the hypertrophic process. [15] [16] [17] [18] [19] [20] [21] [22] In the present study, we have defined the binding specificity of novel HDAC inhibitors (HDACis) and have evaluated the role of specific inhibitors of class I HDACs in the prevention of cardiac hypertrophy in vitro and in vivo. Our data suggest that class I HDAC inhibition has potential use in heart failure.
Methods

In vitro histone deacetylase inhibition assays
C-terminally flag-tagged HDAC1, -2, -3, -6, -9, and -11 were expressed in HEK293 cells, affinity purified using anti-flag antibody affinity resin, and eluted with a 3X flag peptide. HDAC4, -5, -7, and -8 were expressed in Escherichia coli. The obtained molecules were then purified to apparent homogeneity [Coomassie-stained sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)] by nickel affinity then anion-exchange (MonoQ) chromatographies, and finally, by gel filtration. IC 50 values of the inhibitor molecules were then determined using the HDAC Fluorescent Activity Assay (BioMol Research Laboratories).
Histone deacetylase inhibitors
Three HDAC inhibitors, MS27-275, PXD-101, and API-D, were chosen based on suitable pharmacokinetic properties and bioavailability for in vivo studies. MS27-275 is an aminobenzamide 23 with selectivity for HDAC1, -2, and -3 when assayed on a panel of purified HDAC subtypes. PXD-101 belongs to the hydroxamic acid class of inhibitors 24 and inhibits both class I and class II enzymes, albeit with different potencies. The third inhibitor, API-D, is a derivative of the cyclic peptide, apicidin, a structurally novel HDAC inhibitor; 25 it also shows selectivity for HDAC class I subtypes 1, 2, and 3 ( Table 1 ).
In vitro experimentation
Cardiomyocytes (CMs) were obtained as previously described from 3-day-old neonatal Wistar rat pups (Charles River Laboratories). 26 CMs were seeded on gelatin-coated plates and kept overnight in medium containing 15% serum to which mitomycin (Sigma) had been added to inhibit overgrowth of non-cardiomyocytes. Cultures contained ,95% CMs as assessed by immunofluorescence for cardiac troponin I (Chemicon). The morning following seeding, CMs were washed, treated with HDACi and/or phenylephrine (PE), and assayed as described later.
Treatment with histone deacetylase inhibitors and induction of hypertrophy
The morning following seeding, CMs were washed in phosphate buffered saline (PBS) and pre-treated in serum-free medium containing HDACi at the indicated doses. A medium change was done 24 h later, again with serum-free medium containing HDACi. Hypertrophy was then induced by the addition of 50 mM PE. CMs were cultured for a further 48 h before analysis. Vehicle [DMSO (dimethyl sulphoxide)] was used instead of HDACi in Control samples. Where specified, the non-specific HDACi, trichostatin A (TSA), was used as a positive control of HDAC inhibition, and the MEK-1/2 inhibitor, PD 098059 (Calbiochem), was used as a control for the inhibition of PE-induced hypertrophy. 27 
Western blotting
Plates were placed on ice and the CMs washed with ice-cold PBS, scraped and centrifuged. Pelleted CMs were lysed directly in Laemlli's sample buffer, boiled for 3 min, centrifuged, and loaded onto 12% SDS-PAGE. After transfer onto polyvinylidene fluoride, membranes were blocked with 5% milk tris-buffered saline-tween 20 and incubated with the following primary antibodies: anti-acetyl histone H3 and anti-histone H4 (Upstate); anti-acetyl tubulin (Sigma); anti-actin; and anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Chemicon). Secondary antibodies and enhanced chemiluminescence were from Amersham. For in vivo experiments, hearts were snap frozen in liquid N 2 , pulverized with a pestle and mortar, and lysed with radio-immunoprecipitation assay buffer. Sample buffer was then added to the uncleared lysates.
Ribonucleic acid extraction and real-time polymerase chain reaction
For in vitro experiments, total ribonucleic acid (RNA) was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer's instructions. The reverse transcription (RT) reaction was performed using Superscript III reverse transcriptase and random primers (Invitrogen). Real-time polymerase chain reaction (PCR) was performed in an ABI PRISM 7000 instrument (Applied Biosystems) using TaqMan technology for Caspase 3 (Casp3), atrial natriuretic factor (ANF), and skeletal actin (Sk Act), as recommended by the manufacturer.
For in vivo experiments, total RNA was extracted by TRIZOL (Invitrogen) according to the manufacturer's instructions. The RT reaction was then performed as the in vitro experiments. Real-time PCR was performed for Casp3, ANF, brain natriuretic peptide (BNP), Sk Act, and beta-myosin heavy chain (b-MHC).
To detect Casp3, Sk Act, BNP, and b-MHC, TaqMan oligonucleotides (Assay on Demand, Applied Biosystems) were used, whereas for ANF, specific primers (For: 5 0 -GGA GGA GAA GAT GCC GGT AGA-3 0 ; Rev: 5 0 -GCT TCC TCA GTC TGC TCA CTC A-3 0 ) (PRIMM) and a specific probe (FAM-TGA GGT CAT GCC CCC GCA GG-TAMRA) (Applied Biosystems) were designed with the 'Primer Express' Program (Applied Biosystems). The Assays on Demand used are given in the see Supplementary material online, Materials and Methods. All reactions were performed in duplicate. 2 2DDCT values were normalized with the values obtained for amplification of GAPDH (Assay on Demand, Applied Biosystems).
Morphometrical measurements
Before preparing CMs for the analyses mentioned earlier, plates were photographed under a phase contrast microscope at Â200 magnification. Captured images were then analysed with Scion Image software (Scion Corp. Inc.) to obtain CM area data expressed in square pixels.
Immunofluorescence
Fixed CMs were stained with phalloidin-tetramethyl rhodamine iso-thiocyanate (Sigma) or anti-cardiac troponin (Chemicon) and counterstained with 4 0 ,6-diamino-2-phenylindole (DAPI).
2.3.6
Lactate dehydrogenase release and terminal deoxynucleotidyl transferase biotin-2 0 -deoxyuridine 5 0 -triphosphate nick end labelling analysis Culture supernatants were collected after 24 and 72 h of treatment with HDACi. Lactate dehydrogenase (LDH) released into the supernatants was quantified with the CytoTox 96 w Assay Kit (Promega), following the manufacturer's indications. Supernatant from vehicle-treated CMs was used for background subtraction. Data are expressed as arbitrary units.
CMs, seeded in 24-well plates and treated as mentioned earlier, were fixed in paraformaldehyde and processed with a terminal deoxynucleotidyl transferase biotin-2 0 -deoxyuridine 5 0 -triphosphate nick end labelling (TUNEL) kit (Roche), as indicated by the manufacturer. DAPI (Sigma) was used to counterstain the nuclei. Images, captured under a fluorescence microscope, were then analysed to obtain the number of TUNEL-positive nuclei per field. A minimum of 200 cells per point were counted. Data are expressed as a percentage of DAPI-stained nuclei.
In vivo experimentation
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996), and Italian ministerial authorization (art. 7, DL 116/92) was obtained to carry out the experimentation.
Nine-week-old female C57BL/6 mice (Charles River Laboratories) (n ¼ 7 per group) were subjected to transverse aortic constriction (TAC) surgery with standard procedures and then treated intraperitoneally (i.p.) with API-D starting from day 1 after TAC. At the indicated time-points, histological, haematological, echocardiographic, and invasive haemodynamic analyses were carried out as outlined later.
Transverse aortic constriction
On day 0, mice were anaesthetized with a ketamine (100 mg/ kg)-xylazine (2.5 mg/kg) mixture administered i.p. and then connected to a rodent ventilator after tracheal intubation. 22 The chest cavity was opened with scissors by a small incision at the level of the second intercostal space. After isolation of the aortic arch, a 7-0 silk suture was placed around the aorta and a 27-27, 5G needle. The needle was immediately removed to produce an aorta with a stenotic lumen. The chest cavity was then closed with one 6-0 nylon suture and all layers of muscle and skin closed with 6-0 continuous absorbable and nylon sutures, respectively. Sham-operated animals, which underwent surgery without the final tightening of the constrictive suture, were used as Controls. 22 
Administration of histone deacetylase inhibitors
Mice were treated i.p. with 3 mg/kg of API-D per day six times a week for 2 weeks, starting on day 1. This dose was found to be well tolerated. Our data also suggested that higher doses of the compound could be administered safely over prolonged periods and, as a result, we decided to use a slightly higher dose (5 mg/kg per day six times a week for 8 weeks, starting on day 1) for the long-term efficacy studies to increase the likelihood of observing effects in our functional in vivo readouts.
Prior to these experiments, pharmacokinetic data were generated in CD-1 mice (n ¼ 3 mice evaluated per time-point). For this, API-D was solubilized in PEG400:water 1:1 and dosed at 3 mg/kg by i.p. injection. A time-course for API-D plasma concentration was also generated.
Echocardiographic assessment of left ventricular function
Transthoracic echocardiography was performed to evaluate left ventricular (LV) function non-invasively in isoflurane-anaesthetized closed-chest mice using a SONOS 5500 echocardiograph (Agilent Technology) fitted with an 8-15 MHz linear array transducer. LV endsystolic and end-diastolic dimensions, and wall thicknesses were evaluated by 2D M-mode as previously described. 28 Analysis was performed at the specified times before and after TAC.
Invasive haemodynamic assessment of cardiac function
In vivo LV function was assessed by pressure volume catheter. Mice were anaesthetized with ketamine (100 mg/kg) and xylazine (2.5 mg/kg) and connected to a rodent ventilator after endotracheal intubation. Then, bilateral vagotomy cardiac catheterization was performed using a 1.4 French (0.46 mm) conductance catheter (Scisense Inc., London, Ontario, Canada) inserted retrograde through the right carotid artery into the LV. Absolute volume was calibrated, and steady-state pressure and volume measurements were digitally recorded at 1000 (baseline). Pressure and volume measurements were also acquired during transient reduction of venous return. All experiments were carried out blind and data were analysed as previously described. 29 
Histology
Hearts (n ¼ 5 per group) at week 4 of experimentation were quickly removed from anaesthetized mice and processed for histology using standard methods. Longitudinal sections of whole heart (4 mm thick) were stained with Masson's trichrome to evidence fibrosis. The total area affected by fibrosis in the sections obtained was quantified with image analysis software (Software NIS Elements-AR, Nikon Instruments) by two independent pathologists and expressed as mm 2 .
Statistical analysis
Data are expressed as mean + SD. Multigroup comparisons were performed using one-or two-way analysis of variance (ANOVA) with post hoc correction for multiple comparisons as appropriate. For all analyses, P , 0.05 was considered significant.
Results
To explore the effects of the HDACis selected for this study, in vitro experiments on neonatal rat CMs were initially performed. As HDAC suppression would be expected to induce histone hyperacetylation, due to unopposed HAT activity, we examined the acetylation status of two known HDAC targets, nuclear histone H3 and cytosolic a-tubulin, with western blotting of total cellular extracts ( Figure 1A) .
HDACi was added to cultured CMs at various concentrations for 2 h and acetylation then assessed. As expected, all the HDACis used were capable of inducing a significant increase in histone H3 acetylation, thus confirming the efficacy of these inhibitors in suppressing deacetylase activity in a dose-related manner ( Figure 1B) . PXD-101, which also suppresses HDAC6 (a class II HDAC), induced a significant increase in the acetylation of a-tubulin, similarly to the broad spectrum HDACi, TSA, 30, 31 whereas MS27-275 and API-D did not, in line with the notion that these two inhibitors do not affect class II HDACs at the doses used in this assay ( Figure 1C) . Blots performed at 72 h gave similar results (data not shown).
Inhibitors of class I histone deacetylases prevent cardiac myocyte hypertrophy in vitro
To investigate the effect on size, rat neonatal CMs were pretreated with HDACi for 24 h and then treated with PE, a strong inducer of hypertrophy, for a further 48 h (Figure 2A) .
Morphometric measurements indicated that treatment with inhibitors significantly blunted PE-induced hypertrophy at a concentration of 1 mM for MS27-275 and PXD-101, and 0.02 mM for API-D ( Figure 2B) . Moreover, CMs treated with HDACi showed morphological changes, probably due to the fact that these HDACis prevent sarcomere re-organization in response to hypertrophic agonists ( Figure 2C ). 11 Expression of ANF, another parameter of CM hypertrophy, was then assessed by qRT-PCR ( Figure 2D) . The amount of ANF mRNA (messenger RNA) induced by PE treatment was significantly reduced by all HDACis, corroborating the data on cell size. PE-stimulated ANF expression was significantly inhibited at concentrations down to 0.1 mM for MS27-275 and PXD-101, and 0.002 mM for API-D; in contrast, at 10-fold lower concentrations (0.01 and 0.0002 mM, respectively for MS27-275/PXD-101 and API-D) there was little or no effect on PE-induced ANF expression, whereas ANF expression was very low at higher concentrations (10 and 2 mM for MS27-275/PXD-101 and API-D, respectively). Similar results were obtained for Sk Act gene expression (data not shown).
Time-course experiments were then performed for API-D, the most efficient drug among the three. The parameters analysed always demonstrated the efficacy of this inhibitor in reducing PE-induced hypertrophy (see Supplementary material online, Figure S1 ).
Inhibition of cardiac myocyte hypertrophy by histone deacetylase inhibitors is not due to toxicity
HDACis can induce cell death. 32 Therefore, we examined whether HDACi administration induced cytotoxicity in CMs by measuring LDH released by dying cells into the culture medium. Doses of MS27-275 up to 1 mM, PXD-101 up to 0.5 mM, and API-D up to 0.02 mM did not significantly increase LDH release after 24 h (data not shown) or 72 h of treatment ( Figure 3A) .
To evaluate potential pro-apoptotic effects of the HDACis, we analysed genomic deoxyribonucleic acid (DNA) degradation with a TUNEL assay ( Figure 3B ) and Casp3 expression with qRT-PCR (see Supplementary material online, Figure S2 ). After 72 h of treatment, doses of MS27-275 or PXD-101 up to 1 mM, and of API-D up to 0.02 mM did not increase the percentage of TUNEL-positive CMs or the expression of Casp3 mRNA.
Thus, the HDACis did not induce toxic effects within the range of concentrations observed to inhibit hypertrophy, i.e.: 1!0.01 mM for MS27-275, 1 ! 0.1 mM for PXD-101, and 0.02 ! 0.002 mM for API-D.
An apicidin derivative attenuates cardiac hypertrophy in vivo and ameliorates cardiac function after pressure overload
API-D is a synthetic small-molecule derivative of the natural cyclic tetrapeptide, apicidin. We decided to use API-D to explore the efficacy in preventing cardiac hypertrophy and heart failure induced by the TAC pressure-overload model. Our choice for this compound was dictated by a series of favourable properties, i.e. good pharmacokinetics in a preclinical species with predicted human once-a-day oral dosing; good tolerability and efficaciousness at low doses in pre-clinical oncology models; and no off-target activities in counter screening (on 150 enzymes/receptors) ( 25 and Phillip Jones et al., unpublished results). These properties compare favourably with those reported for MS275, which is not tolerated well in man and has a short T 1/2 , 33 and PXD-101, a hydroxamic acid with short T 1/2 and poor selectivity. 34 As a result of its molecular properties, API-D is effective at a concentration lower than other compounds, and has better pharmacokinetic properties when compared with TSA or the other HDACis tested ( 25 and Phillip Jones et al., unpublished results). In particular, the following pharmacokinetic data were obtained for 3 mg/kg API-D Thus, 9-week-old female C57BL/6 mice were injected with API-D i.p. starting on the day after TAC, and analyses were performed as indicated ( Figure 4A) . We observed significantly lower LV and heart weight to body weight (BW) ratios in TAC-operated animals treated with API-D compared with those that were not treated; no significant differences were observed within sham groups ( Figure 4B and see Supplementary material online, Tables S1 and S2), whereas % FS (fractional shortening) did not differ between the groups ( Figure 4C) . No differences were found in terms of survival (data not shown), BW, or haematological parameters (see Supplementary material online, Figure S3 ).
Increased expression of embryonic cardiac genes (ANF, b-MHC, and Sk Act) is a hallmark of myocardial stress during pressure overload. To test whether in vivo API-D treatment modifies the expression of these genes, we measured the relative abundance of these mRNAs in LV extracts by qRT-PCR ( Figure 4D) . As expected, mRNA of all three genes was significantly higher in mice subjected to TAC compared with sham-operated animals (P , 0.05). In API-D-treated TAC-operated mice, the increase in b-MHC and Sk Act was significantly reduced. Moreover, histone H3 was more acetylated in myocardial extracts of API-D-treated animals ( Figure 4E) .
We then studied the effect of API-D on myocardial functional and biological parameters after 8 weeks of TAC, the point when mice present with a decompensated form of cardiac hypertrophy. To this end, 9-week-old female C57BL/6 mice were injected with API-D i.p. from day 1 of TAC, and analysed as outlined in Figure 5A . At the end of the experiment, LV/BW ratio was found significantly lower in the API-D-treated TAC-operated group than in the untreated one; no significant differences were observed between sham groups ( Figure 5B) . Other parameters of cardiac hypertrophy, such as LV mass index, diastolic interventricular septum thickness, and diastolic LV posterior wall thickness were all significantly less in the API-D-treated TAC-operated group with respect to the untreated counterpart ( Figure 5C ). LV diastolic diameter was also significantly less in TAC-operated mice when treated with API-D. Moreover, percentage fractional shortening was significantly higher in the API-D-treated TAC-operated group with respect to the untreated TAC-operated one ( Figure 5C ).
As expected, haemodynamic evaluation showed a markedly depressed systolic function in untreated TAC-operated mice. The first derivative of LV pressure (dP/dt max ) was found significantly improved in the group of TAC-operated mice treated with API-D compared with the untreated counterpart ( Table 2) . Positive effects on cardiac function were confirmed also by two independent parameters of cardiac relaxation, the minimum first derivative of LV pressure (dP/dt min ) and exponential t (the time constant of LV pressure decay), suggesting a better diastolic cardiac performance and, indirectly, reduced myocardial fibrosis.
In addition, a significantly lower Sk Act mRNA level was measured in the LV of the API-D-treated TAC-operated group compared with the untreated TAC-operated one ( Figure 5D) ; ANF and b-MHC mRNAs were slightly reduced.
To assess whether treatment with API-D decreases fibrotic reaction, hearts were processed for histology, stained with Masson's trichrome, and the total area affected by fibrosis (i.e. stained in blue) was measured in whole-heart sections ( Figure 6) . The area of fibrosis occurring with TAC (9.9 Â 10 6 + 0.8 Â 10 6 mm 2 ) was significantly (two-way ANOVA with Bonferroni post-test, P , 0.05) reduced by treatment with API-D (5.5 Â 10 6 + 0.5 Â 10 6 mm 2 ).
No differences were found between the untreated and API-D-treated sham-operated groups in terms of survival, Casp3 expression (measured by qRT-PCR on RNA samples extracted from LV tissue), and BW (see Supplementary material online, Tables S1 and S2). Moreover, haematological parameters were within the norm for all groups (see Supplementary material online, Figure S4 ).
Discussion
We have focused on the characterization of new HDAC inhibitors, describing an apidicin derivative with a specific HDAC class I inhibiting activity in particular. API-D is part of a structurally novel family of HDAC inhibitors since it neither contains a hydroxamic acid (as does PXD-101) nor a benzamide moiety (as does MS27-275), but it is thought to bind to the HDAC active site Zn þ ion via a hydrated ketone group. 25 Our data demonstrate that the use of this compound blunts hypertrophic cardiac growth in mice and, thus, has positive effects on heart failure progression without producing any obvious side effects.
Cardiac myocytes (CM) respond to stress by activating gene expression programs. Many transcription factors have been identified that are critical for the induction of specific genes activated during hypertrophy. 35 The post-genomic era, however, has shown that transcription factors are not the unique key regulators of gene expression. Epigenetic mechanisms such as DNA methylation, post-translational modifications of histone proteins, remodelling of nucleosomes, and expression of small regulatory RNAs all contribute to regulation of gene expression and determination of cell and tissue specificity. These mechanisms are reversible and represent potential targets for therapeutic intervention. The regulation of gene expression through histone acetylation has been demonstrated to be particularly relevant and complex for CM growth and myocardial hypertrophy. 13, 36, 37 Class I and class II HDACs seem to have opposite effects on hypertrophic pathways. Class II HDACs repress hypertrophy, 9, 38 whereas class I HDACs are required for some aspects of the hypertrophic response. Inhibitors that block the catalytic activity of both class I and class II HDACs prevent hypertrophic responses in both isolated myocytes and intact mice, suggesting that the predominant targets of these chemical inhibitors are class I HDACs. 11, 39 Recently, it was proposed that HDAC2, among the class I HDACs, is a major target of HDAC inhibitors in the heart, indicating this HDAC as a target for the treatment of cardiac hypertrophy and heart failure. 14 Knockout of HDAC2 was demonstrated to increase expression of the gene encoding inositol polyphosphate-5phosphatase f, resulting in constitutive activation of glycogen synthase kinase-3beta via inactivation of Akt and 3-phosphoinositide-dependent protein kinase-1. 14 Inhibition of cardiac hypertrophy in vivo by either generic or class I-specific HDAC inhibitors was found to improve cardiac function and blunt fibrosis significantly. 12, 40 Overall, our data obtained with the novel compound, API-D, together and in agreement with the literature suggest that the beneficial effect of HDAC inhibition includes attenuation of fibrosis and reduced switching of contractile protein isoforms.
We acknowledge the limitations of our study in that it is relatively underpowered and that it does not compare in vivo all the inhibitors used in the study, but the functional improvement seen in the mice was found to be significant with relatively low doses of API-D. The small but significant blunting of hypertrophy produced with this compound may not explain the improved heart function totally, and as yet unknown mechanisms, apart from transcriptional-related ones, might be involved. On this point, a very recent report has revealed that HDACs influence cardiac function at an extra-nuclear level: 41 treatment of cardiomyocytes with HDAC inhibitors results in an increased acetylation of sarcomeric proteins that enhances myofilament calcium sensitivity. Muscle LIM protein-the cytosolic target of HDAC4, a class II HDAC, and PCAF, a HAT-was found to be central to this mechanism. Thus, protein acetylation is another layer of regulation controlling muscle physiology that might be targeted when using HDAC inhibitors; we do not exclude the possibility that API-D might also affect cardiac function through altered acetylation of sarcomeric proteins, perhaps indirectly through an effect mediated by class II HDACs. In fact, in that report, the class I HDAC inhibitor, MS275, was found to have an effect that was comparable with that of the generic HDAC inhibitors, TSA and scriptaid.
Despite in vitro data, which clearly demonstrate reduced expression of hypertrophy markers, data obtained in vivo can be more difficult to interpret. In fact, the expression of ANF in vivo has been reported to be profoundly affected in one instance, 40 whereas in another report the effect of HDAC inhibition on ANF expression was limited. 12 We observed in vivo that the ANF transcript level was increased in API-D-treated TAC-operated mice to a similar extent as untreated TAC-operated mice even if hypertrophy was significantly blunted in the former; on the other hand, b-MHC and Sk Act were reduced. E. Olson's lab reported a similar discrepancy between in vitro and in vivo ANF levels after the use of TSA. 11, 12 An enhancement of gene expression in general is a consequence of HDAC inhibition; therefore, generic transcriptional effects could a be reason for confounding mRNA expression levels in vivo.
Dissection of the mechanisms underlying HDAC inhibition represents a continuing challenge in cardiology. In oncology, these drugs are already under clinical trials for the treatment of cancer. Because class I HDAC inhibition prevents cardiac hypertrophy induced by pressure overload and greatly improves heart function, HDAC inhibitory compounds hold promise to be a new pharmacologic tool also for the treatment of heart failure.
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